These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 2784529)
1. Monoamine oxidase inhibitory properties of milacemide in rats. Truong DD; Diamond B; Pezzoli G; Mena MA; Fahn S Life Sci; 1989; 44(15):1059-66. PubMed ID: 2784529 [TBL] [Abstract][Full Text] [Related]
2. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. Janssens de Varebeke P; Cavalier R; David-Remacle M; Youdim MB J Neurochem; 1988 Apr; 50(4):1011-6. PubMed ID: 3346666 [TBL] [Abstract][Full Text] [Related]
3. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B. Janssens de Varebeke P; Pauwels G; Buyse C; David-Remacle M; De Mey J; Roba J; Youdim MB J Neurochem; 1989 Oct; 53(4):1109-16. PubMed ID: 2769256 [TBL] [Abstract][Full Text] [Related]
4. Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex. Semba J; Doheny M; Patsalos PN; Sarna G; Curzon G Br J Pharmacol; 1992 Jan; 105(1):59-62. PubMed ID: 1596690 [TBL] [Abstract][Full Text] [Related]
5. Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions? O'Brien EM; Tipton KF; Strolin Benedetti M; Bonsignori A; Marrari P; Dostert P Biochem Pharmacol; 1991 Jun; 41(11):1731-7. PubMed ID: 2043162 [TBL] [Abstract][Full Text] [Related]
6. Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells. Yadid G; Zinder O; Youdim MB Br J Pharmacol; 1991 Nov; 104(3):760-4. PubMed ID: 1797336 [TBL] [Abstract][Full Text] [Related]
7. MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice. Colombo M; Strolin Benedetti M; Bonsignori A; Cocchiara G; Roncucci R; Dostert P J Neural Transm Suppl; 1990; 32():123-9. PubMed ID: 2089081 [TBL] [Abstract][Full Text] [Related]
8. Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B. O'Brien EM; Dostert P; Tipton KF Biochem Pharmacol; 1995 Jul; 50(3):317-24. PubMed ID: 7646533 [TBL] [Abstract][Full Text] [Related]
9. Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase. O'Brien EM; Dostert P; Pevarello P; Tipton KF Biochem Pharmacol; 1994 Aug; 48(5):905-14. PubMed ID: 8093103 [TBL] [Abstract][Full Text] [Related]
10. Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat. Khandwala H; Loomis CW Pain; 1998 Jul; 77(1):87-95. PubMed ID: 9755023 [TBL] [Abstract][Full Text] [Related]
11. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Semba J; Curzon G; Patsalos PN Br J Pharmacol; 1993 Apr; 108(4):1117-24. PubMed ID: 8485621 [TBL] [Abstract][Full Text] [Related]
12. Does FAD-dependent polyamine oxidase contribute to the metabolism of milacemide? Strolin Benedetti M; Cocchiara G; Colombo M; Dostert P J Neural Transm Suppl; 1990; 32():351-6. PubMed ID: 2128509 [TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insluin secretion. Feldman JM; Chapman B Diabetologia; 1975 Dec; 11(6):487-94. PubMed ID: 1107123 [TBL] [Abstract][Full Text] [Related]
15. Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells. Godfraind JM Br J Pharmacol; 1990 May; 100(1):119-25. PubMed ID: 2196964 [TBL] [Abstract][Full Text] [Related]
16. The interactions of milacemide with monoamine oxidase. O'Brien EM; Tipton KF; McCrodden JM; Youdim MB Biochem Pharmacol; 1994 Feb; 47(4):617-23. PubMed ID: 8129740 [TBL] [Abstract][Full Text] [Related]
17. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694 [TBL] [Abstract][Full Text] [Related]
18. Modulation of vocal and nonvocal behavior in adult squirrel monkeys by selective MAO-A and MAO-B inhibition. Newman JD; Winslow JT; Murphy DL Brain Res; 1991 Jan; 538(1):24-8. PubMed ID: 1902133 [TBL] [Abstract][Full Text] [Related]
19. Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker. Ashkenazi R; Finberg JP; Youdim MB Br J Pharmacol; 1983 Jul; 79(3):765-70. PubMed ID: 6418248 [TBL] [Abstract][Full Text] [Related]
20. Inactivation of monoamine oxidase B by analogues of the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide). Nishimura K; Lu X; Silverman RB J Med Chem; 1993 Feb; 36(4):446-8. PubMed ID: 8474100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]